Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options

Dimple Chakravarty, Li Huang, Matthew Kahn, Ashutosh K. Tewari

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


The advent of immunotherapy has revolutionized cancer treatment. Prostate cancer has an immunosuppressive microenvironment and a low tumor mutation burden, resulting in low neoantigen expression. The consensus was that immunotherapy would be less effective in prostate cancer. However, recent studies have reported that prostate cancer does have a high number of DNA damage and repair gene defects. Immunotherapies that have been tested in prostate cancer so far have been mainly vaccines and checkpoint inhibitors. A combination of genomically targeted therapies, with approaches to alleviate immune response and thereby make the tumor microenvironment immunologically hot, is promising.

Original languageEnglish
Pages (from-to)487-510
Number of pages24
JournalUrologic Clinics of North America
Issue number4
StatePublished - Nov 2020


  • Checkpoint inhibition therapy
  • Immunotherapy
  • Preclinical models
  • Prostate cancer
  • Vaccines


Dive into the research topics of 'Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options'. Together they form a unique fingerprint.

Cite this